Applicability and performance of 18F-FDG PET-based modalities for whole-body cancer screening: a systematic review and meta-analysis

被引:0
|
作者
Das, K. J. [1 ]
Meena, J. K. [2 ]
Kumar, D. [3 ]
机构
[1] All India Inst Med Sci AIIMS, Natl Canc Inst NCI AIIMS, Dept Nucl Med, New Delhi, India
[2] All India Inst Med Sci AIIMS, Natl Canc Inst NCI AIIMS, Dept Prevent Oncol, New Delhi, India
[3] Vardhman Mahavir Med Coll & Safdarjung Hosp, Dept Nucl Med, New Delhi, India
关键词
Screening; Early detection; PET scan; F-18-FDG PET; Cancer prevention; POSITRON-EMISSION-TOMOGRAPHY; CLINICAL-SIGNIFICANCE; OVEREXPRESSION; PET/MRI; BREAST;
D O I
10.1007/s11604-024-01659-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Screening tests are the cornerstone for early detection and optimal management of cancers. Most of the present cancer-screening tests are intrusive, time-consuming, and specifically target a particular anatomical site or cancer type. Only a few studies have reported the objective measures of F-18-FDG PET-based cancer screening in asymptomatic individuals. This review and meta-analysis is an attempt to assess the applicability and performance of F-18-FDG PET-based modalities for whole-body cancer screening. Materials and methods The systematic review and meta-analysis were performed following PRISMA guidelines. Literature searches in PubMed, Scopus, and Embase were conducted using relevant MeSH terms and keywords, for articles published in the last 2 decades (2000-2022). Pooled estimates of diagnostic test accuracy-including sensitivity, specificity, positive-likelihood ratio, negative-likelihood ratio, and hierarchical summary ROC (HSROC) curve were generated using bivariate random-effects meta-analysis. Results Seventeen studies were included in the systematic review and 13 studies were deemed eligible for meta-analysis. The mean estimates of pooled sensitivity, specificity, positive-likelihood ratio, negative-likelihood ratio, and Odds ratio using F-18-FDG PET with a 95% confidence interval were 0.47 (0.25-0.69), 0.97 (0.95-0.98), 18.8 (6.8-51.5), 0.45 (0.27-0.76), 41.0 (7.9-211.8) and for F-18-FDG PET/CT were 0.83 (0.75-0.88), 0.98 (0.97-0.99), 49.7 (29.2-84.5), 0.15 (0.8-0.28), 329.9 (125.0-870.8), respectively. Among screening modalities, F-18-FDG PET/CT had a higher accuracy i.e., the area under the HSROC curve (AUC): 0.91 (0.87-0.95) compared to F-18-FDG PET: 0.72 (0.61-0.82). Conclusion This study demonstrates that currently F-18-FDG PET-based screening has limited applicability for population-based cancer-screening programs. However, it has a promising role as a combined screening strategy for at-risk individuals and allows for comprehensive diagnostic and prognostic evaluation in high-resource settings.
引用
收藏
页码:266 / 281
页数:16
相关论文
共 50 条
  • [31] Whole-body 18F-FDG PET/CT in Uveal Melanoma Patients
    Pursanova, D. M.
    Mukhortova, O. V.
    Aslanidis, I. P.
    Katunina, T. A.
    Saakyan, S. V.
    Avakyan, K. V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S585 - S586
  • [32] Autoimmune pancreatitis: whole-body 18F-FDG PET/CT findings
    Jian Zhang
    Chengwei Shao
    Jianhua Wang
    Chao Cheng
    Changjing Zuo
    Gaofeng Sun
    Bin Cui
    Aisheng Dong
    Qinghua Liu
    Lingshan Kong
    Abdominal Imaging, 2013, 38 : 543 - 549
  • [33] Whole-body 18F-FDG PET/CT in the presence of truncation artifacts
    Beyer, T
    Bockisch, A
    Kühl, H
    Martinez, MJ
    JOURNAL OF NUCLEAR MEDICINE, 2006, 47 (01) : 91 - 99
  • [34] Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma
    Yen, RF
    Hong, RL
    Tzen, KY
    Pan, MH
    Chen, THH
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (05) : 770 - 774
  • [35] Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis
    Ma, Huan
    Shen, Guohua
    Liu, Bin
    Yang, Yuanyou
    Ren, Pengwei
    Kuang, Anren
    NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (02) : 156 - 163
  • [36] Autoimmune pancreatitis: whole-body 18F-FDG PET/CT findings
    Zhang, Jian
    Shao, Chengwei
    Wang, Jianhua
    Cheng, Chao
    Zuo, Changjing
    Sun, Gaofeng
    Cui, Bin
    Dong, Aisheng
    Liu, Qinghua
    Kong, Lingshan
    ABDOMINAL IMAGING, 2013, 38 (03): : 543 - 549
  • [37] Whole-Body 18F-FDG PET-CT in the Diagnosis of Neurosarcoidosis
    Fritz, Daan
    van de Beek, Diederik
    Brouwer, Matthijs C.
    Booij, Jan
    MAYO CLINIC PROCEEDINGS, 2020, 95 (05) : 1082 - 1084
  • [38] 18F-FDG-avid plantar nodules on true whole-body 18F-FDG PET/CT in cancer patients
    Muzaffar, Razi
    Raslan, Osama
    Osman, Medhat M.
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (09) : 881 - 886
  • [39] A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT
    Lu, Yu-Yu
    Chen, Jin-Hua
    Ding, Hueisch-Jy
    Chien, Chun-Ru
    Lin, Wan-Yu
    Kao, Chia-Hung
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (11) : 1127 - 1133
  • [40] Combined early dynamic 18F-FDG PET/CT and conventional whole-body 18F-FDG PET/CT in hepatocellular carcinoma
    Zhang, Yiqiu
    Dong, Yun
    Yu, Wenjun
    Chen, Shuguang
    Yu, Haojun
    Li, Beilei
    Shi, Hongcheng
    ABDOMINAL RADIOLOGY, 2023, 48 (10) : 3127 - 3134